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Chronic graft-versus-host disease (cGVHD) is an autoimmune-like syndrome, and donor B cells play
important roles in augmenting its pathogenesis. B celledepleting anti-CD20 mAb has been administered
before or after cGVHD onset for preventing or treating cGVHD in the clinic. Although administration before
onset appeared to be more effective, the effect is variable and sometimes minimal. Here, we used 2 mouse
cGVHD models to evaluate the preventive and therapeutic effect of anti-CD20 mAb. With the model of DBA/2
donor to MHC-matched BALB/c recipient, 1 intravenous injection of anti-CD20 mAb (40 mg/kg) the following
day or on day 7 after hematopoietic cell transplantation when serum autoantibodies were undetectable
effectively prevented induction of cGVHD and preserved a strong graft-versus-leukemia (GVL) effect. The
separation of GVL effect from GVHD was associated with a signiﬁcant reduction of donor CD4þ T cell pro-
liferation and expansion and protection of host thymic medullary epithelial cells. Anti-CD20 mAb adminis-
tration also prevented expansion of donor T cells and induction of cGVHD in another mouse model of C57BL/6
donor to MHC-mismatched BALB/c recipients. In contrast, administration of anti-CD20 mAb after GVHD onset
was not able to effectively deplete donor B cells or ameliorate cGVHD in either model. These results indicate
that administration of anti-CD20 mAb before signs of cGVHD can prevent induction of autoimmune-like
cGVHD while preserving a GVL effect; there is little effect if administered after cGVHD onset. This provides
new insights into clinical prevention and therapy of cGVHD with B celledepleting reagents.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is a
curative therapy for hematological malignancies such as leu-
kemia and lymphoma [1]. Although donor T cells including
CD4þ and CD8þ in transplants play a critical role in mediating
graft-versus-leukemia/lymphoma (GVL) effects and prevent-
ing tumor relapse, alloreactive T cells also mediate a severe
side effect called graft-versus-host disease (GVHD), a major
obstacle for widespread application of allogeneic HCT [2-6].
Although both CD4þ and CD8þ Tcells can induce GVHD, CD8þ
T cells are more potent than CD4þ T cells in mediating GVL
effect [7-15].
GVHD is initiated by alloreactive T cell inﬁltration of
GVHD target tissues (ie, gut, skin, liver, lung, and thymus) inedgments on page 1101.
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14.04.028recipients conditioned with total body irradiation (TBI) or
high-dose chemotherapy [16]. The conditioning procedure
causes local tissue inﬂammation and attracts alloreactive
T cell inﬁltration [17]. GVHD can be divided into acute and
chronic states. Acute GVHD (aGVHD) is characterized by se-
vere inﬁltration of lymphocytes and other mononuclear cells
and tissue cell apoptosis [18,19]. Chronic GVHD (cGVHD)
usually follows aGVHD and has overlapping target organs
with aGVHD, but some cGVHD can occur with little prior
aGVHD and has prototypical target organs such as the sali-
vary gland [20-22]. cGVHD is a systemic lupus- and multiple
sclerodermaelike autoimmune syndrome characterized
with chronic inﬂammation as well as autoantibody and
collagen tissue deposition [20,23-26]. Although current
immunosuppressive therapy can effectively prevent aGVHD,
these drugs have little effect in preventing cGVHD, and
cGVHD remains the major cause of morbidity and mortality
in long-term survivors after allogeneic HCT [19,27-29].
Studies by our group and others have demonstrated that
autoimmune-like cGVHD is mediated by both donor CD4þ T
and B cells [10,21,22,26,30], which can derive from matureTransplantation.
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ment in a GVHD-damaged thymus deﬁcient in proper
negative selection [21,22,26,31-33]. We recently showed that
the pathogenic CD4þ T and B cells in cGVHD recipients
mediate mutual activation and expansion [22]. Donor B cells
can be an effective antigen presenting cell (APC) that medi-
ates autoreactive CD4þ T cell clonal expansion, because
depletion of donor B cells in transplants prevent the
expansion of autoreactive CD4þ T cells that mediate persis-
tent inﬂammation in GVHD target tissues. Once expanded,
autoreactive CD4þ T cells can mediate cGVHD pathogenesis
in the absence of donor B cells [22]. It has also been reported
that lymphopenia in cGVHD recipients leads to an unbal-
anced ratio of B cell-activating factor of the tumor necrosis
factor family (BAFF)-to-B cell numbers and expansion of
autoreactive B cells [34]. In addition, allo- and autoantibody
production and tissue deposition is associated with cGVHD
pathogenesis [35,36].
Thymic damage in cGVHD recipients is usually thought to
be an outcome of aGVHD-mediated by alloreactive T cells in
transplants, and the alloreactive T cell damage of the thymus
has been shown to be dependent on Fas/FasL and TRAIL/DR5
pathways but not the perforin/granzyme pathway [14,37,38],
which is in contrast to the GVL effect, which was shown to be
more dependent on the perforin/granzyme pathway
[14,15,38,39]. Our recent studies showed that besides donor
T cells in transplants, de novoedeveloped donor-type CD4þ
Tcells but not CD8þ Tcells in GVHD recipients early after HCT
contribute to perpetuation of thymus damage [26].
Anti-CD20 mAbs (such as rituximab) can deplete CD20þ
normal B cells and B cell lymphoma cells [40-47], and the
mechanisms of depletion include monocyte-mediated anti-
body-dependent cellular cytotoxicity, antibody-dependent
cellular phagocytosis, and complement-dependent cytotox-
icity [48-52]. Administration of B celledepleting anti-CD20
mAb was reported to prevent a variety of autoimmune
diseases such as type 1 diabetes, arthritis, and thyroiditis
[53-56], because depletion of B cells by anti-CD20 mAb
inhibited expansion of antigen-speciﬁc autoreactive CD4þ
T cells [57]. Administration of anti-CD20 mAb after disease
onsetwas reported tobe ineffective in reversal of autoimmune
type 1 diabetes because of inﬁltrating B cells down-regulating
their expression of CD20 [54], although anti-CD20 mAb was
effective in treating ongoing autoimmune thyroiditis [53].
Rituximab has been used to treat corticosteroid-
dependent cGVHD as a second-line treatment with varying
efﬁcacy [58-61]. More recent reports showed that adminis-
tration of rituximab at 2 to 3months after HCTand before the
onset of cGVHD appeared to be more effective than after
onset [62,63]; treatment was able to deplete B cells and
either prevented cGVHD or patients developed less severe
cGVHD [62]. Administration of rituximab before cGVHD
onset was safe and did not increase tumor relapse rates or
incidence of infection [62]. These trials suggest that earlier
administration of rituximab is likely to be more effective
than later administration; however, it remains unclear how
to clinically deﬁne the appropriate time of administration to
obtain optimal prevention of cGVHD.
We developed 2 separate models of cGVHD. In the ﬁrst
model, transplantation of high-dose DBA/2 donor spleen
cells into MHC-matched BALB/c recipients and donor CD4þ T
and B cells in transplants play an important role in mediating
cGVHD [21,22,30,64]; in the secondmodel, transplantation of
low-dose donor C57BL/6 spleen cells into MHC-mismatched
BALB/c recipients and de novoedeveloped donor CD4þ T andB cells play an important role in mediating cGVHD [26].
Pathogenic CD4þ T and B cells can derive from mature T and
B cells in transplants or arise from de novo development in a
GVHD-damaged thymus. Additionally, B cells are capable of
down-regulating CD20 expression [54], and pathogenic
CD4þ Tcells canmediate cGVHD pathogenesis in the absence
of B cells after prior expansion by B cells [22,26]. Therefore,
we tested whether administration of anti-CD20 mAb the
following day after HCT or “early” after HCT (before clinical
manifestations) could prevent induction of cGVHD and also
whether administration of anti-CD20 mAb at cGVHD onset
could ameliorate ongoing cGVHD in our 2 cGVHD models.
We found that administration of anti-CD20 mAb the
following day after HCT or before the appearance of serum
autoantibodies was able to effectively deplete donor B cells,
protect the host thymus, and prevent induction of cGVHD in
both models and that anti-CD20 mAb treatment did not
interfere with the GVL effect. On the other hand, adminis-
tration of anti-CD20 mAb at the time of GVHD onset was less
effective in depleting donor B cells and did not ameliorate
ongoing GVHD. These studies indicate that administration of
anti-CD20 mAb before autoreactive CD4þ T and B cell
expansion and autoantibody production is required for
effective prevention of cGVHD.
METHODS
Mice
C57BL/6, DBA/2, and BALB/c mice were purchased from the National
Cancer Institute animal production program (Frederick, MD). Rag-2/
BALB/c mice were purchased from Taconic Farms (Germantown, NY). Rag-
2/DBA/2micewere developed in the City of Hope Animal Resource Center
(Duarte, CA). Igm/ C57BL/6 mice were purchased from Jackson Labora-
tories (Bar Harbor, ME). Mice were maintained in a pathogen-free room in
the City of Hope Animal Resource Center. All animal protocols were
approved by the City of Hope Institutional Animal Care and Use Committee.
Statistical Analysis
Clinical cutaneous damage scoring and survival in different groups were
compared by using the rank sum test or log-rank test (Prism, version 5.0;
GraphPad Software, San Diego, CA). Comparison of 2 means was analyzed
using an unpaired 2-tailed Student t-test.
Antibody, Flow Cytometry Analysis, and Cell Sorting
PE CD4 (GK1.5), FITC CD5.1 (H11-86.1), FITC B220 (RA3-6B2), FITC H-2Kb
(AF6-88.5), and Paciﬁc Blue CD45R were purchased from BD Pharmingen
(San Diego, CA). APC-CD8a (53-6.7), APC-eFluor 780 TCRb (H57-597), and
PE-Cy7 TCRb (H57-597) were purchased from eBioscience (San Diego, CA).
Alexa Fluor 488 goat anti-mouse IgG (HþL), Streptavidin Alexa Fluor 555,
and Alexa Fluor 488 donkey anti-rat IgG (HþL) were purchased from Life
Technologies (Grand Island, NY). DAPI dilactate was purchased from Sigma
(St. Louis, MO). Biotinylated Ulex europaeus agglutinin (UEA) I was pur-
chased from Vector Laboratories (Burlingame, CA). Aqua ﬂuorescent reactive
dye for viability analysis was purchased from Invitrogen (Carlsbad, CA). APC
CD20 (18B12) was the kind gift of David Serreze (Jackson Laboratory, Bar
Harbor, ME) [54]. Flow cytometry experiments were performed and run on a
CyAn Immunocytometry system (Dako Cytomation, Fort Collins, CO), and
the resulting data were analyzed with FlowJo software (Tree Star, Ashland,
OR) [21,22,64]. Puriﬁed anti-CD20 mAb (isotype IgG2a, 5D2) was the kind
gift of Genentech (San Francisco, CA).
Induction and Assessment of GVHD
Mice were exposed to 850 cGy TBI with the use of a [137Cs] source
8 hours before HCT. Recipients were injected i.v. with either DBA/2 CD25þ
celledepleted spleen cells and whole bone marrow (BM) cells or C57BL/6
whole spleen cell and T and B celledepleted BM (TBCD-BM). CD25 depletion
in the spleen and T and B cell depletion in the BM were accomplished using
biotin-conjugated anti-CD25 (spleen) and biotin-conjugated anti-CD3, anti-
CD4, anti-CD8, anti-B220, and anti-CD19 mAb (BM) and anti-biotin micro-
magnetic beads, followed by passage through an autoMACS cell sorter
(Miltenyi Biotec, San Diego, CA). The purity of depletion was >99%. The
assessment and scoring of clinical cutaneous GVHD was described previ-
ously [21,22,65]. Assessment and scoring of total GVHD was as follows: hair
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weight loss (if no proteinuria occurred) (0 to 2).
Tissue Collection for Cellular Analysis
Mice were killed using CO2 asphyxiation, and their spleens and thy-
muses were collected for analysis. Single-cell suspensions were prepared by
mashing tissues through a 70-mm ﬁlter.
Thymic Epithelial Cell Staining and Serum Autoantibody
Staining of Rag-2/ Mouse Skin, Salivary Gland, and
Lung Tissues
Thymic epithelial staining was performed on cryosections of recipients’
thymuses at various time points after HCT. Serum autoantibodies were
measured by staining thymuses of Rag-2/-BALB/c and -DBA/2 mouse skin,
salivary gland, and lung tissues as previously described [26,66]. In brief,
cryosections from thymuses of recipients, Rag-2/ BALB/c or Rag-2/ DBA/
2 mice, were prepared by soaking tissues in 4% paraformaldehyde for
>1 hour followed by dehydration in a solution of 30% sucrose in PBS. Tissue
was then frozen in optimal cutting temperature gel and cryosectioned.
Cryosections were placed in acetone at e20C for 30 minutes and then
rehydrated in PBS containingMg2þ. Tissueswere blockedwith 10% FBS in PBS
for 2 hours. Tissues were then incubated overnight with either Biotin UEA-I
(thymic epithelial cell staining) or diluted serum (autoantibody staining) and
washed again. Tissueswere then stainedwith either streptavidin-Alexa Fluor
555 (thymic epithelial cell staining) or anti-mouse IgG Alexa Fluor 488
(autoantibody staining) and DAPI for 2 hours and washed. Representative
photographs were taken of each tissue at 100 with an Olympus BX51 and a
Pixera (600CL) cooled charge-coupled device camera (Olympus, Melville, NY;
Pixera, Santa Clara, CA). Quantiﬁcation of antibody staining was done using
Image-Pro Premier 9.1 (Rockville, MD). Serum autoantibody staining was
quantiﬁed using integrated optical density of Alexa Fluor 488 luminosity per
pixel of each slide. UEA-I staining of thymic epithelia was quantiﬁed using
sum luminosity of Alexa Fluor 555 of each slide.
Bioluminescent Imaging
Mice were injected with luciferaseþ BCL1 cells (BCL1/Lucþ) i.p. at
time of transplantation and monitored for expansion of those cells using
bioluminescent imaging. In vivo imaging of tumor growth was previously
described [67]. Mice were injected with 200 mL ﬁreﬂy luciferin i.p.
(Caliper Life Sciences, Hopkinton, MA), anesthetized, and imaged using
an IVIS100 charge-coupled device imaging system (Xenogen, Alameda,
CA). Data were analyzed using Igor Pro 4.0 software purchased from
WaveMetrics (Lake Oswego, OR).
RESULTS
Administration of Anti-CD20 mAb Effectively Prevented
Induction of Autoimmune-Like cGVHD in BALB/c
Recipients Given MHC-Matched Donor DBA/2 BM
Transplants
We reported that depletion of donor B cells in transplants
effectively prevented induction of autoimmune-like chronic
GVHD in BALB/c recipients givenMHC-matched donor DBA/2
transplants [22]. Thus, we tested whether administration of
anti-CD20mAb at the time of HCTcould prevent induction of
autoimmune-like cGVHD.
Accordingly, lethally irradiated BALB/c recipients
(850 cGy TBI) were injected with CD25þ T celledepleted
spleen (CD25-SPL) cells (75  106) and BM cells (2.5  106)
from DBA/2 donors. The following day after transplant, re-
cipients were given 1 injection of anti-CD20 mAb (40 mg/kg,
clone 5D2, IgG2a). Injection of this anti-CD20 mAb was re-
ported to begin depleting splenic B cells within 16 hours of
injection, and the depletion could last for about 2 months,
similar to another anti-CD20 mAb (clone MB20-11, IgG2c)
[57,68]. Consistently, we observed that 1 injection of this
anti-CD20 mAb the following day after HCT effectively
depleted B220þ B cells (>95%) for more than 25 days
(Supplementary Figure 1). Percentage of B cells recovered
was similar to control recipients given BM alone byw60 days
after HCT (data not shown) and remained similar 100 daysafter HCT (Supplementary Figure 1). Although all recipients
(12/12) treated with rat IgG developed proteinuria, showed
signs of clinical GVHD, and died approximately 25 days after
HCT, all recipients (12/12) treated with anti-CD20 mAb
showed no proteinuria and little clinical signs of GVHD and
survived for more than 100 days (P < .01, Figure 1A-C). The
anti-CD20 mAbetreated recipients looked similar to control
recipients given BM alone (Figure 1A-C).
Twenty-ﬁve days after HCT, whereas all rat IgG-treated
recipients had very small thymuses with few CD4þCD8þ
thymocytes, anti-CD20mAbetreated recipients had a similar
percentage and yield of CD4þCD8þ thymocytes to that of
GVHD-free control recipients given BM alone, and this
remained similar 100 days after HCT (Figure 1D). The anti-
CD20 mAbetreated long-term survivors showed no tissue
damage in cGVHD target tissues such as skin, lung, and
salivary gland (data not shown). These results indicate that
administration of anti-CD20 mAb at the beginning of HCT is
able to effectively prevent induction of autoimmune-like
cGVHD.Administration of Anti-CD20 mAb Effectively Preserved
GVL Effect in BALB/c Recipients Given MHC-Matched
Donor DBA/2 BM Transplants While Preventing Induction
of cGVHD
We evaluated the impact of anti-CD20 mAb administra-
tion on the GVL effect. Lethally TBI-conditioned BALB/c mice
were injected with newly thawed (BCL1/Lucþ) leukemia/
lymphoma cells (25  106) and transplanted with BM
(2.5  106) alone or BM þ CD25--SPL cells (75  106) from
DBA/2 donors. Anti-CD20 mAb (40 mg/kg) or rat IgG was
administered the following day after HCT. Tumor cell growth
was monitored with in vivo bioluminescent imaging every
5 days for up to 75 days. As shown in Figure 2A and B, the
BCL1/Lucþ tumor cells grew rapidly in recipients given BM
alone plus control rat IgG and killed all mice (8/8) by
approximately 20 days after tumor cell injection. The BCL1/
Lucþ tumor cells gradually disappeared and became unde-
tectable in mice injected with BM and anti-CD20 mAb by
approximately 10 days after injection, but the tumor came
back w20 days and killed all mice (8/8) by w25 days after
tumor cell injection. The recipients injected with BM plus
spleen cells and control rat IgG eliminated tumor cells by
w10 days after injection, but themice developed proteinuria,
and nearly all (7/8) died of GVHD by 25 days after HCT. One
mouse did survive GVHD, but tumor also relapsed and the
mouse died of tumor load w45 days after HCT. In contrast,
the recipients injected with BM plus spleen cells and anti-
CD20 mAb eliminated the tumor cells, and all (8/8) sur-
vived for more than 75 days with no tumor or little signs of
GVHD (P < .01). These results indicate that anti-CD20 mAb
treatment the following day after HCT preserves GVL effect
while preventing GVHD.Preventing Induction of cGVHD by Anti-CD20 mAb
Treatment Was Associated with Prevention of Production
of Antibodies against Donor- and Host-Type GVHD Target
Tissues
We recently reported that cGVHD recipients developed
antibodies against both donor- and host-type GVHD target
tissues [26]. Antibodies against host tissues were reported to
contribute to cGVHD pathogenesis, especially in the lung
[69]. We used skin, lung, and salivary gland of host-type
Figure 1. Anti-CD20 mAb prevents induction of cGVHD in BALB/c recipients given MHC-matched donor DBA/2 BM transplants. Lethally irradiated BALB/c recipients
were transplanted with spleen cells (75  106) and BM cells (2.5  106) from DBA/2 donors and injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/kg) the
following day. Control recipients were given BM cells alone. Recipients were monitored for clinical GVHD, including hair loss, proteinuria, and survival (y indicates
death of all recipients in a group). (A-C) Percentage of recipients without (A) proteinuria, (B) clinical cutaneous GVHD score, and (C) percentage of survival. Each group
contained 20 recipients combined from 5 replicate experiments. (D) Twenty-ﬁve and 100 days after HCT, recipients thymuses were measured for percentage of
CD4þCD8þ thymocytes, and a representative pattern is shown of 4 replicate experiments.
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sues. As shown in Figure 3A and B, sera from day 7 HCT re-
cipients of all groups showed no staining of either donor- or
host-type tissues. Sera from rat IgG-treated GVHD recipients
on days 15 and 25 showed strong staining of the target tis-
sues; no later time points were available because of GVHD
death. At the same time, sera from anti-CD20 mAbetreated
GVHD-free recipients showed little staining of GVHD target
tissues, even at 100 days after HCT when the B cell popula-
tion was totally recovered (Figure 3). These results suggest
that administration of anti-CD20mAb the following day after
HCT not only depletes pre-existing autoreactive B cells in
transplants but also prevents de novo generation of autor-
eactive B cells, such that autoantibody production is
completely prevented, and that this may contribute to pre-
venting induction of cGVHD.
Preventing Induction of cGVHD by Administration of
Anti-CD20 mAb the Following Day after HCT Is Associated
with Reduction of Donor CD4þ but Not CD8þ T Cell
Proliferation and Expansion
We compared the percentage and yield of total donor-
type T cells as well as CD4þ and CD8þ subsets in recipients
treated with anti-CD20 mAb or control rat IgG the following
day after HCT. As compared with rat IgG treatment, anti-
CD20 mAb treatment did not consistently change the per-
centage or yield of total donor-type T cells in the spleen of
recipients at days 7, 15, and 25 after HCT (Supplementary
Figure 2). However, anti-CD20 mAb treatment decreased
the percentage and yield of donor-type CD4þ Tcells at days 7,15, and 25 after HCT, especially 15 days after HCT (P < .01,
Figure 4A,B). Conversely, anti-CD20 mAb treatment
increased the percentage of donor-type CD8þ T cells (P < .01,
Figure 4A,C). This relative increase resulted from the
decrease of donor-type CD4þ T cells. Anti-CD20 mAb treat-
ment signiﬁcantly decreased donor-type CD4þ T prolifera-
tion as judged by in vivo BrdU-labeling (P < .01, Figure 4D).
Anti-CD20 mAb treatment did not change the activation
status (as judged by CD62L and CD44 staining), did not
change the apoptosis rate (as judged by Annexin V staining),
and did not change the percentage of IFN-ae, IL-17e, or IL-
4eproducing cells among donor-type CD4þ T cells (as judged
by intracellular staining; data not shown). Anti-CD20 mAb
treatment did not signiﬁcantly change the percentage of
regulatory T cells among donor-type CD4þ T cells or the
percentage of IL-10eproducing regulatory B cells among
residual donor B cells (data not shown). These results indi-
cate that anti-CD20 mAb treatment reduced donor-type
CD4þ T cell proliferation and expansion but did not change
differentiation or apoptosis rate of donor-type CD4þ T cells
early after HCT; in addition, anti-CD20 mAb treatment had
little negative impact on donor CD8þ T cell expansion.
Preventing Induction of cGVHD by Administration of
Anti-CD20 mAb the Following Day after HCT Is Associated
with Protection of Thymic Epithelial Cells and Thymocyte
Production
Our recent studies showed that damage of thymic med-
ullary epithelial cells was associated with production of
autoreactive CD4þ T cells that caused persistent thymic
Figure 2. Anti-CD20 mAb prevents induction of cGVHD while preserving GVL effects in BALB/c recipients given MHC-matched donor DBA/2 BM transplants. Lethally
irradiated BALB/c recipients were transplanted with spleen cells (75  106) and BM cells (2.5  106) from DBA/2 donors. Control recipients were given BM cells alone.
Luciferase positive B-cell leukemia/lymphoma 1 cells (BCL1/Lucþ) (25  106) were injected i.p. at the same time when donor BM and spleen cells were injected i.v.
Twelve hours later mice were injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/kg). Recipients were monitored daily for signs of tumor and clinical GVHD,
including hair loss, proteinuria, and survival and in vivo imaging. (A) In vivo imaging shows progression of tumor over time. One representative image from each time
point with at least 4 mice for time point is shown for each group. (B) Photons/sec (107) of recipients in each group, percentage of recipients without proteinuria, and
survival. Each group comprises 6 to 8 mice combined from 3 replicate experiments.
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yield of CD4þCD8þ thymocytes reﬂect the thymic regenera-
tion capacity [70]. Thus, we evaluated the impact of anti-
CD20 mAb treatment on thymic production of CD4þCD8þ
(double positive, DP) thymocytes and thymic medullary
epithelial cell (mTEC) recovery at days 7, 15, 25, and 100 after
HCT. The percentage of DP thymocytes in control recipients
given donor BM only was w.5% at day 7 after HCT, but it
rapidly increased and reached more than 75% by 15 days
after HCT and was stable for up to 100 days (Figure 5A, top
row). The percentage of DP thymocytes of rat IgG-treated
GVHD recipients was w.1% at day 7, w8% at day 15, and
dropped back tow.7% at day 25. No recipients in this group
survived for more than 30 days.In contrast, the percentage of DP thymocytes of anti-CD20
mAbetreated GVHD-free recipients wasw.3% at day 7,w14%
at day 15,w68% at day 25, andw75% at day 100. The yield of
CD4þCD8þ thymocytes of rat IgG-treated GVHD mice was
w40-fold lower as compared with anti-CD20 mAbetreated
recipients 25 days after HCT (P< .01), although no signiﬁcant
difference was observed between anti-CD20 mAbetreated
and control recipients given BM alone on days 7, 15, 25, and
100 days after HCT (Figure 5A).
Fifteen days after HCT, the thymus of rat IgG-treated
GVHD recipients was much smaller than GVHD-free re-
cipients given donor BM alone or anti-CD20 mAb treatment,
although the latter 2 visibly appeared to be similar in size
(data not shown) and yield (Figure 5A). Immunoﬂuorescent
Figure 3. Anti-CD20 mAb treatment prevents production of serum autoantibodies against skin, salivary gland, and lung. (A and B) Representative photographs
(original magniﬁcation 100) of (A) Rag-2/ BALB/c and (B) Rag-2/ DBA/2 skin, salivary gland, and lung tissues with GVHD recipient serum autoantibodies from
days 7, 15, 25, and 100 after HCT are shown. DAPI staining is shown in blue, and autoantibody staining is shown in green. One representative staining is shown from 4
mice per group per time point. Average integrated optical density (OD) is shown of serum autoantibody staining from four mice per group per time point.
H.F. Johnston et al. / Biol Blood Marrow Transplant 20 (2014) 1089e11031094
Figure 4. Anti-CD20 mAb reduces donor CD4þ T proliferation and expansion. Lethally irradiated BALB/c recipients were transplanted with spleen cells (75  106) and
BM cells (2.5  106) from DBA/2 donors and injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/kg). (A) Percentage of splenic CD4þ and CD8þ donor T cells
(CD5.1þ TCRbþ) was measured 7, 15, and 25 days after HCT. A representative pattern from each group at each time point is shown. Mean  SE of percentage of (B)
splenic CD4þ and (C) CD8þ donor T cells (CD5.1þ TCRbþ) was measured 7, 15, and 25 days after HCT with 5 to 8 recipients at each time point from each group
combined from 4 replicate experiments. (D) Mice were injected with 2.5 mg of BrdU 24 hours before being killed on day 7. Left: A representative staining pattern
showing splenic donor Brduþ CD4þ T cells gated on CD5.1þ TCRbþ. Right: Mean  SE of percentage and yield of splenic CD5.1þ TCRbþ Brduþ CD4þ T cells (n ¼ 4).
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Figure 5. Anti-CD20 mAb protects thymic epithelial cells and thymocyte regeneration. Lethally irradiated BALB/c recipients were transplanted with spleen cells
(75  106) and BM cells (2.5  106) from DBA/2 donors and injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/kg). Control recipients were given BM cells alone.
(A) Seven, 15, 25, and 100 days after HCT, recipients were measured for percentage and yield of CD4þCD8þ thymocytes. A representative staining pattern is shown
from 4 to 8 mice for each group at each time point from 3 replicate experiments. (B) One representative photograph (original magniﬁcation 100) of the kinetic
changes of thymic epithelial structure is shown 15, 25, and 100 days after HCT from 4 sections per mouse with 4 mice per time point. Thymic medullary epithelial
cells are shown with UEA-I (red) as well as DAPI (blue). Average sum luminosity is shown of UEA-I staining (red) of thymic epithelia from 4 mice per group per time
point.
H.F. Johnston et al. / Biol Blood Marrow Transplant 20 (2014) 1089e11031096staining showed that UEA-Iþ mTECs were detectable in the
medulla of all 3 recipient types 15 days after HCT (Figure 5B,
left column). However, 25 days after HCT the UEA-Iþ mTEC
cells became undetectable in rat IgG-treated GVHD re-
cipients but appeared to have an expansion in the thymus of
anti-CD20mAbetreated GVHD-free recipients and BM-alonerecipients (Figure 5B, middle column). One hundred days
after HCT, the mTEC staining patterns in the thymus of
GVHD-free control recipients and anti-CD20 mAbetreated
recipients appeared to be similar (Figure 5B, right column).
These results indicate that further thymic damage in GVHD
recipients can occur after emergence of de novoedeveloped
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vents further thymic damage and allows for rapid recovery of
thymic mTECs and de novo generation of thymocytes.
Administration of Anti-CD20 mAb before but Not after
GVHD Onset Is Effective in Depleting B Cells, Protecting
Thymus, and Preventing cGVHD
Administration of anti-CD20 mAb after the presence of
autoantibodies in serum was reported to be ineffective in
depleting B cells or preventing autoimmune type 1 diabetes
onset in NOD mice due to B cell down-regulation of CD20 in
inﬂammatory tissues [54]. We also observed that sera from
GVHD recipients after day 15 but not day 7 showed allo- and
autoreactivity against host- and donor-type GVHD target
tissues (Figure 3). Additionally, donor-type B cells gradually
increased at days 7, 15, and 25 in the spleen after HCT
(Supplementary Figure 1), and their CD20 expression levels
trended downward by days 15 and 25, resulting in a signif-
icant reduction in the percentage of CD20þ B cells in control
nontreated mice (P < .05), although there was no difference
between day 7 and before HCT (Figure 6A,B). Thus, we
compared the effect of administration of anti-CD20 mAb
starting on day 7 or 15 after HCT in preventing or amelio-
rating cGVHD.
Accordingly, 1 group of recipients was administered anti-
CD20 mAb on days 7, 15, and 20, referred to as day 7 treat-
ment, and the other group was administered anti-CD20 mAb
on days 15 and 20, referred to as day 15 treatment. Addi-
tionally, a no treatment group was used as a control. Control
recipients all developed proteinuria by day 16 and died by
day 26 after HCT. Recipients given day 15 treatment showed
similar proteinuria and survival curve to the control re-
cipients. However, recipients given day 7 treatment showed
delayed onset of proteinuria with reduced severity and re-
covery by 35 days after HCT. All these recipients survived for
more than 50 days without further development of signs of
GVHD; this is a marked difference from the group given day
15 treatment (P < .01, Figure 6C).
Additionally, HCT recipients from the 3 groups were
analyzed for percentage of B220þ B cells and CD4þ and CD8þ
T cells in the spleen, as well as percentage and yield of
CD4þCD8þ thymocytes, on day 25 after HCT. Day 7 treatment
effectively depleted B cells, and the percentage of residual
B cells was only w.5%, a more than 30-fold reduction as
comparedwith control recipients, and the yield of B cells was
also reduced byw5-fold (P< .01, Figure 6D). This was similar
to treatment starting the following day after HCT (Figure 6D,
Supplemental Figure 1). In contrast, day 15 treatment was
less effective in depleting B cells, and the percentage of re-
sidual B cells wasw4.1%, which wasw8-fold higher than day
7 treatment (P < .01). Day 15 treatment did not signiﬁcantly
reduce the yield of spleen B cells as compared with control
recipients (Figure 6D).
Day 7 treatment signiﬁcantly reduced the percentage of
donor CD4þ T cells but increased the percentage of CD8þ
T cells in the spleen 25 days after HCT, as compared with
control mice (P < .01, Figure 6E). However, day 15 treatment
did not make signiﬁcant changes to these populations and
appeared to be similar to control recipients (Figure 6E). On
the other hand, day 7 treatment markedly increased the
percentage and yield of CD4þCD8þ thymocytes as compared
with control mice (P < .01, Figure 6F), whereas day 15
treatment produced no difference compared with control
mice (Figure 6F). These results indicate that administration
of anti-CD20 mAb before but not after presence ofautoantibodies or GVHD onset is able to effectively deplete
donor B cells, reduce donor CD4þ T cell expansion, protect
the thymus, and prevent development of cGVHD.
Administration of Anti-CD20 mAb Prevented Induction of
cGVHD in BALB/c Recipients Given Low-Dose MHC-
Mismatched C57BL/6 Donor Transplants
We recently reported that transplantation of high-dose
(5  106) C57BL/6 donor spleen cells and BM cells
(2.5  106) into myeloablative TBI-conditioned MHC-mis-
matched BALB/c recipients caused lethal aGVHD but trans-
plantation of low-dose (1.25  106) donor cells induced
severe autoimmune-like cGVHD [26]. We also observed that
de novoedeveloped donor B cells markedly augmented
cGVHD in this model, because BALB/c recipients given low-
dose donor C57BL/6 CD8þ T cells (0.5  106) induced severe
cGVHD in recipients givenwild-type donor BM that produced
de novoedeveloped B cells but the CD8þ T cells induced little
signs of cGVHD in recipients given Igm/ donor BM that did
not produce de novoedeveloped B cells (Supplementary
Figure 3). Thus, we tested how administration of anti-CD20
mAb impacts the induction of aGVHD and cGVHD.
We observed that administration of anti-CD20 mAb
(40 mg/kg) or rat IgG the following day after HCT of high-
dose (5  106) spleen cells plus TBCD-BM (2.5  106) from
C57BL/6 donors did not prevent induction of aGVHD, because
all 8 recipients in both anti-CD20 mAbeand rat IgG-treated
groups developed severe body weight loss, clinical signs of
GVHD, and died by 7 days after HCT; there was no difference
between the two groups (Supplementary Figure 4). In
contrast, administration of anti-CD20 mAb the following day
after HCT effectively prevented induction of cGVHD in re-
cipients given low-dose (1.25  106) donor spleen cells as
judged by prevention of body weight loss and hair loss
60 days after HCT (P < .01, Figure 7A), although almost all
recipients in each group survived for more than 60 days after
HCT. Compared with GVHD-free recipients given donor BM
alone, 50 days after HCT the rat IgG-treated GVHD recipients
showed a marked increase of percentage of donor-type
T cells but a marked decrease of the donor-type T cell yield,
although there was no signiﬁcant changes in ratio of CD4þ
versus CD8þ T cells (P< .01, Figure 7B). In contrast, anti-CD20
mAbetreated GVHD-free recipients appeared to be similar to
recipients given BM alone in the percentage and yield of
donor-type T cells (Figure 7B).
Administration of anti-CD20 mAb the following day after
HCT also protected the thymus. Although rat IgG-treated
GVHD recipients had little CD4þCD8þ (DP) thymocytes in
percentage or yield 50 days after HCT, anti-CD20 mAbe
treated GVHD-free recipients had a percentage and yield of
DP thymocytes similar to GVHD-free recipients given BM
alone (Figure 7C). In addition, administration of anti-CD20
mAb starting 45 days after HCT upon GVHD development
did not ameliorate the disease as judged by equally severe
body weight loss and hair loss (Supplementary Figure 5).
These results indicate that administration of anti-CD20 mAb
the following day after HCT is able to prevent induction of
cGVHD in MHC-mismatched recipients that do not have se-
vere aGVHD. Administration of anti-CD20 mAb does not
prevent aGVHD or ameliorate cGVHD after its onset.
DISCUSSION
With MHC-matched and -mismatched cGVHDmodels we
observed the following. First, administration of anti-CD20
mAb within 7 days of HCT when serum autoantibodies
Figure 6. Administration of Anti-CD20 mAb at different time points after HCT is associated with differential B cell depletion, donor CD4þ T cell expansion, thymus
protection, and GVHD. Lethally irradiated BALB/c recipients were transplanted with spleen cells (75  106) and BM cells (2.5  106) from DBA/2 donors and injected
i.v. with anti-CD20 mAb (40 mg/kg) on days 7, 15, and 20 (Day 7 Treatment) or days 15 and 20 (Day 15 Treatment) or nothing (Control). (A and B) Some control (no
treatment) recipients were killed on days 7, 15, and 25 after HCT and splenic B220þCD20þ percentage and yields were measured and a representative pattern is
shown (n ¼ 4 before, Day 7, Day 15; n ¼ 3 Day 25). (C) Recipients were monitored for clinical GVHD, including proteinuria and survival (y indicates death of all
recipients in a group) (n ¼ 8). (D) Four recipients from each group were killed on day 25 and percentage and yield of splenic B220þ cells were measured (right) and a
representative staining pattern from each group is shown (left). (E) Four recipients from each group were killed on day 25 and a representative splenic staining
pattern gated on CD5.1þ TCRbþ (left) of CD4þ and CD8þ donor T cells (right) is shown. (F) Twenty-ﬁve days after HCT, 4 recipients from each group were measured for
percentage and yield of CD4þCD8þ thymocytes (right) and a representative pattern is shown (left).
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Figure 7. Anti-CD20 mAb prevents induction of cGVHD in BALB/c recipients given MHC-mismatched C57BL/6 donor T cells. Lethally irradiated BALB/c recipients were
injected with 1.25  106 whole spleen cells and 2.5  106 TBCD-BM cells from C57BL/6 donors and injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/kg) the
following day. Recipients given TBCD-BM alone were used as controls. (A) Recipients were monitored for clinical GVHD, including body weight change, clinical
cutaneous cGVHD score, and survival (n ¼ 12). (B and C) Recipients from each group were killed on day 50 and (B) percentage and yield of splenic CD4þ and CD8þ
donor T cells (H2KbþTCRbþ) percentage and (C) yield of CD4þCD8þ thymocytes were measured. A representative staining pattern from each group at each time point
is shown from 4 mice from 2 replicate experiments.
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tion of cGVHD. Second, the cGVHD-preventative effect was
associated with effective depletion of donor B cells, and
delayed administration after clinical signs of GVHD already
appeared (proteinuria andpresence of serumautoantibodies)
failed to effectively deplete donor B cells or reverse GVHD.Third, effective prevention of induction of cGVHD is associ-
ated with the preservation of strong GVL effects.
Our observations suggest that the timing of administra-
tion of anti-CD20 mAb is critical, and the sooner the
administration of anti-CD20 mAb, the better the cGVHD
preventative effect. We observed that administration of
H.F. Johnston et al. / Biol Blood Marrow Transplant 20 (2014) 1089e11031100anti-CD20 mAb the following day after HCT prevented in-
duction of cGVHD in 100% of recipients; administration of
anti-CD20 mAb starting 7 days after HCT when serum
autoantibodies were undetectable could still effectively
prevent induction of cGVHD, although some recipients
developed transient and reversible proteinuria. However,
administration of anti-CD20 mAb after cGVHD onset did not
have any effect in either MHC-matched or -mismatched
models. The ineffectiveness of cGVHD prevention by delayed
administration of anti-CD20 mAb was associated with a
reduced depletion of donor B cells. We observed that
administration of anti-CD20mAb the following day after HCT
reduced the percentage of B220þ B cells on day 25 from
w12% to w.2%, administration at 7 days after HCT still
reduced it to <1%, and administration at 15 days after HCT
reduced it to 4.1% with no reduction in total spleen B cell
yield. In addition, the inability to reverse ongoing GVHD
15 days after HCT might also be associated with pre-existing
pathogenic CD4þ T cells that were expanded by donor B cells
before the anti-CD20 mAb depletion. Our report indicates
that after an initial expansion of pathogenic CD4þ T cells by
donor B cells, B cells are no longer required for continued
GVHD pathogenesis [22].
Our observations with mousemodels are consistent with
clinical studies. Administration of anti-CD20 mAb (ritux-
imab) to patients with refractory cGVHD achieved variable
and minimal effect in ameliorating the disease [59,60,71],
and administration of anti-CD20 mAb 2 to 3 months after
HCT, that is, before cGVHD onset, signiﬁcantly reduced
severity of cGVHD as judged by a signiﬁcant reduction in
corticosteroid-requiring cGVHD and nonrelapse-related
mortality, although patients still developed oral cGVHD
[62]. Because administration of anti-CD20 mAb did not
appear to increase relapse rate or infection incidence [62], it
would be of interest to test whether administration of
anti-CD20 mAb earlier than 2 months after HCT would be
more effective in preventing induction of cGVHD. It would
also be of interest to test whether occurrence of auto-
antibodies in the serum could serve as a prognostic
biomarker for predicting the effect of anti-CD20 mAb ther-
apy for prevention of cGVHD, because current studies
showed that administration of anti-CD20 mAb before but
not after presence of autoantibodies in the serum could
effectively prevent induction of cGVHD in a mouse model.
This thought is consistent with reports that increased BAFF-
to-B cell ratio after HCT could be a biomarker for predicting
cGVHD development, and anti-CD20 mAb treatment that
effectively ameliorated cGVHD reduced the BAFF-to-B cell
ratio [72,73].
Autoantibodies can be produced by donor B cells in
transplants and de novoedeveloped B cells in GVHD re-
cipients. Our previous reports indicate that early alloimmune
response after HCT leads to activation of donor CD4þ T cells
that possess both donor and host reactivity, and those CD4þ
T cells interact with autoreactive B cells in transplants to
induce autoantibody production and mediate cGVHD path-
ogenesis [21,22]. Supplemental data in our current report
indicate that cGVHD induced by T cells in transplants is
augmented by de novoedeveloped B cells.
We observed that delayed administration of anti-CD20
mAb was associated with less effective depletion of donor
B cells. Consistent with previous reports that B cell lym-
phoma cells [42,74] and activated B cells in the pancreas of
type 1 diabetes NOD mice became resistant to anti-CD20
mAb depletion via down-regulation of CD20 expression[54], we also observed that the CD20 expression levels on
B cells in the spleen trended down after HCT, although the
drop in CD20 expressionwas quite small. This can contribute
to ineffective depletion of B cells by delayed administration
of anti-CD20 mAb, but other factors can also be of impor-
tance for HCT recipients. We observed that HCT recipients
often appeared to be mixed chimeric 7 days after HCT but
became complete chimeric by 15 days after HCT. A recent
report showed that the primary mechanism of depletion by
anti-CD20 mAb requires the presence of liver Kupffer cells to
mediate antibody-dependent phagocytosis [68]. The same
anti-CD20 antibody is used in the current studies. Therefore,
it is likely that the ineffective depletion of B cells by anti-
CD20 mAb 15 days after HCT is due to the lack of liver
Kupffer cells, because at that time, host-type Kupffer cells
have been ablated in the liver and donor-type Kupffer cells
have yet to take up residence. This warrants further inves-
tigation. In addition, activated B cells can up-regulate
expression of FcgRIIb and become more resistance to anti-
CD20 mAbeinduced apoptosis [75]; however, we observed
little difference in FcgRIIb levels on donor B cells after HCT
(data not shown).
It is of interest that administration of anti-CD20mAb after
HCT was able to protect recipient thymus and prevent in-
duction of cGVHD in BALB/c recipients transplanted with
MHC-matched DBA/2 or MHC-mismatched C57BL/6 donor
spleen cells. As we know, cGVHD can be mediated by
autoreactive CD4þ T and B cells in transplants or de
novoedeveloped autoreactive CD4þ T and B cells after
aGVHD [21,26]. The cGVHD model of DBA/2 donor to BALB/c
recipient is 1 model that has an ampliﬁed role of donor CD4þ
T and B cells in transplants in the induction of cGVHD,
because a large amount of DBA/2 donor spleen cells
(w50  106) induced weak aGVHD but strong cGVHD
[21,22,30]. The cGVHD model of C57BL/6 to BALB/c is one
model with an ampliﬁed role of de novoedeveloped donor
CD4þ T and B cells in mediating cGVHD, because donor
C57BL/6 spleen cells generally induced severe lethal aGVHD,
but a small dose (<1.25  106) of donor spleen cells allowed
for the induction of cGVHD after thymic damage [26].
In both models, we found that depletion of donor B cells
by anti-CD20mAbwas able to augment thymic epithelial cell
regeneration and prevent aGVHD’s transition into cGVHD. It
is not yet clear how depletion of donor B cells lead to pro-
tection of thymic epithelial cells. Because we found that de
novoedeveloped donor-type autoreactive CD4þ T cells early
after HCT were responsible for persistent thymic damage
mediated by alloreactive T cells in transplants [26], and
because it was reported that B cells mediate expansion of
autoreactive CD4þ T cells that recognize low levels of auto-
antigen [76], we hypothesize that depletion of donor B cells
prevents the expansion of autoreactive CD4þ T cells derived
from both mature CD4þ T cells in transplants and de
novoegenerated CD4þ T cells from an aGVHD-damaged
thymus. The prevention of autoreactive CD4þ T cell expan-
sion can prevent thymic epithelial damage, because our
recent publication showed that autoreactive CD4þ T cells can
perpetuate thymus damage initiated by alloreactive T cells
from the transplants [26]. This protection allows for survival
of radiation-resistant IL-22eproducing lymphoid inducer
cells [77] to augment regeneration of thymic epithelial cells.
Future studies will test this hypothesis.
It is also of interest that early administration of anti-CD20
mAb after HCT prevented induction of cGVHD while pre-
serving strong GVL effects. We found that anti-CD20 mAb
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cantly reduced the proliferation and yield of donor-type
CD4þ T cells. In contrast, anti-CD20 mAb treatment did not
change the donor CD8þ T cell activation status, proliferation,
or yield. Previous reports proposed that B cells mediated
expansion of CD4þ T cells responsive to low levels of auto-
antigen [76]; thus, depletion of donor B cells by anti-CD20
mAb may reduce the expansion of donor-type CD4þ T cells
that mediate cGVHD pathogenesis, that is, CD4þ T cells that
possess both donor and host reactivity and recognize the
nonpolymorphic antigens expressed by both donor and host
tissues, as proposed by our and other previous publications
[21,22,78]. Additionally, donor CD4þ T cells were reported to
use FasL/Fas pathway to kill target cells [37,38], and FasL/Fas
and TRAIL/DR5 pathways were shown to play more impor-
tant roles in thymic damage than the perforin/granzyme
pathway [37]. On the other hand, alloreactive donor CD8þ
T cells play a more important role than CD4þ T cells in
mediating GVL effect via the perforin/granzyme pathway
[15,38,39]. Therefore, it is conceivable that although deple-
tion of donor B cells by anti-CD20 mAb can inhibit donor
CD4þ T cell expansion, prevent persistent thymic damage,
and prevent induction of cGVHD, depletion of B cells does not
interfere with donor CD8þ T cell activation or expansion or
their GVL effects. Our recent report indicates that donor
CD8þ T cells do not induce cGVHD in the absence of help
from pathogenic CD4þ T cells [26].
In addition, although administration of anti-CD20 the
following day after HCT did not have an obvious impact on
induction of aGVHD in MHC-mismatched HCT of C57BL/6
donor to BALB/c recipient in the current studies, adminis-
tration of B celledepleting anti-CD20 mAb (rituximab) pre-
and peritransplantation was reported to reduce aGVHD in
HCT patients given MHC-matched donor transplants in some
cases, although it was not consistently effective in prevention
of cGVHD [79-83]. aGVHD is mediated mainly by alloreactive
T cells. In MHC-mismatched recipients, alloreactive T cells
receive enough stimulation that the contribution of donor
B cells to their activation and expansion is negligible. The
reduction of aGVHD by depletion of donor B cells in MHC-
matched patient recipients may result from the reduction
of expansion of alloreactive T cells. We reported that in MHC-
matched HCT recipients, donor B cells can expand donor
T cells that have both allo- and autoreactivity [21]. The lack of
prevention of cGVHD may be due to the short duration of
B cell depletion. We observed that donor B cells in trans-
plants or de novoedeveloped after HCT could augment in-
duction of cGVHD. Thus, injection of depleting anti-CD20
mAb after HCT for a long enough time period, that is,
depletion of de novoedeveloped donor B cells for a certain
time period, may be required for preventing induction of
cGVHD.
In summary, administration of anti-CD20 mAb 1 to 7 days
after HCT (before the appearance of autoantibodies) effec-
tively prevented induction of cGVHD and preserved the GVL
effect. Administration starting at day 15 (upon GHVD onset
and autoantibody appearance) did not ameliorate ongoing
GVHD. These observations in combination with others’ re-
ports suggest that to obtain the optimal effect in prevention
of aGVHD and cGVHD development, anti-CD20 mAb should
be administered before and after HCT for a period of time
beyond the usual time point for aGVHD onset. Once aGVHD
occurs, administration of anti-CD20 mAb alone may no
longer be effective, because by that time donor B cells may
have already down-regulated CD20 and autoreactive CD4þT cells may have already been expanded. Thus, after aGVHD
onset, the effective approach for ameliorating aGVHD and
preventing cGVHD should be depleting the activated donor
B and CD4þ T cells by administration of anti-CD20 mAb
and other B celledepleting antibodies such anti-CD22/
calicheamicin-conjugate mAb in combination with anti-
CD4 mAb or antithymocyte globulin to deplete T cells. Anti-
CD22 calicheamicin-conjugate mAb has been reported to
be an effective reagent for depleting mature B cells [84,85].
Addition of antithymocyte globulin and anti-CD20 mAb to
the conditioning regimen was reported to be more effective
in the prevention of GVHD [82]. Whether administration of
depleting anti-CD20 and anti-CD4 mAb can yield optimal
prevention of aGVHD and cGVHD while preserving GVL ef-
fects need to be tested in future studies, because anti-CD4
mAb can spare donor CD8þ T cells that mediate GVL effects.ACKNOWLEDGMENTS
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